loading
Precedente Chiudi:
$2.41
Aprire:
$2.45
Volume 24 ore:
1.04M
Relative Volume:
0.52
Capitalizzazione di mercato:
$194.40M
Reddito:
$78.12M
Utile/perdita netta:
$-153.22M
Rapporto P/E:
-0.8074
EPS:
-2.96
Flusso di cassa netto:
$-136.90M
1 W Prestazione:
-13.72%
1M Prestazione:
-36.44%
6M Prestazione:
-56.62%
1 anno Prestazione:
-76.38%
Intervallo 1D:
Value
$2.30
$2.47
Intervallo di 1 settimana:
Value
$2.30
$2.80
Portata 52W:
Value
$2.30
$11.69

Editas Medicine Inc Stock (EDIT) Company Profile

Name
Nome
Editas Medicine Inc
Name
Telefono
617-401-9000
Name
Indirizzo
11 HURLEY ST., CAMBRIDGE, MA
Name
Dipendente
226
Name
Cinguettio
@editasmed
Name
Prossima data di guadagno
2024-11-04
Name
Ultimi documenti SEC
Name
EDIT's Discussions on Twitter

Confronta EDIT con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
EDIT 2.39 194.40M 78.12M -153.22M -136.90M -2.96
VRTX 449.47 115.43B 10.63B -479.80M -1.35B 13.33
REGN 749.23 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 589.07 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 247.16 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 107.06 24.89B 3.30B -501.07M 1.03B 11.54

Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-08-08 Aggiornamento BofA Securities Neutral → Buy
2024-05-09 Aggiornamento Morgan Stanley Underweight → Equal-Weight
2023-10-24 Aggiornamento Citigroup Neutral → Buy
2023-10-18 Aggiornamento JP Morgan Underweight → Neutral
2023-10-17 Downgrade Cantor Fitzgerald Overweight → Neutral
2023-09-29 Aggiornamento Stifel Hold → Buy
2023-06-12 Aggiornamento Raymond James Mkt Perform → Outperform
2023-02-01 Iniziato Cantor Fitzgerald Overweight
2022-12-13 Iniziato Citigroup Neutral
2022-12-06 Ripresa Credit Suisse Neutral
2022-11-18 Downgrade Credit Suisse Outperform → Neutral
2022-11-18 Downgrade Oppenheimer Outperform → Perform
2022-09-29 Iniziato BofA Securities Neutral
2021-10-19 Iniziato SVB Leerink Mkt Perform
2021-09-24 Iniziato Stifel Hold
2021-09-10 Aggiornamento Oppenheimer Perform → Outperform
2021-08-09 Aggiornamento Truist Hold → Buy
2021-08-05 Aggiornamento Evercore ISI Underperform → Outperform
2021-06-04 Ripresa Robert W. Baird Outperform
2021-05-04 Iniziato RBC Capital Mkts Sector Perform
2021-04-16 Iniziato Goldman Sell
2021-03-22 Iniziato Credit Suisse Outperform
2021-03-01 Downgrade Barclays Overweight → Equal Weight
2021-02-26 Downgrade Truist Buy → Hold
2021-01-19 Downgrade Morgan Stanley Equal-Weight → Underweight
2021-01-07 Downgrade Raymond James Outperform → Mkt Perform
2020-12-10 Aggiornamento Wells Fargo Equal Weight → Overweight
2020-11-03 Iniziato Robert W. Baird Underperform
2020-06-18 Ripresa SunTrust Buy
2020-02-21 Iniziato Wells Fargo Equal Weight
2019-04-12 Iniziato Evercore ISI Outperform
2018-10-10 Iniziato Guggenheim Neutral
2018-09-21 Iniziato Raymond James Outperform
2018-05-15 Reiterato Chardan Capital Markets Buy
2018-02-13 Iniziato CLSA Underperform
2018-01-23 Aggiornamento SunTrust Hold → Buy
2017-07-14 Iniziato SunTrust Hold
2017-03-28 Iniziato Chardan Capital Markets Buy
2016-08-10 Aggiornamento Jefferies Hold → Buy
2016-06-02 Iniziato Jefferies Hold
2016-02-29 Iniziato JMP Securities Mkt Outperform
2016-02-29 Iniziato JP Morgan Neutral
2016-02-29 Iniziato Morgan Stanley Equal-Weight
Mostra tutto

Editas Medicine Inc Borsa (EDIT) Ultime notizie

pulisher
Nov 20, 2024

EDIT Stock Drops Amid Market Volatility in Biotech Sector - GuruFocus.com

Nov 20, 2024
pulisher
Nov 20, 2024

Little Excitement Around Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues As Shares Take 34% Pounding - Simply Wall St

Nov 20, 2024
pulisher
Nov 20, 2024

Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y - MSN

Nov 20, 2024
pulisher
Nov 18, 2024

Editas Medicine, Inc. (NASDAQ:EDIT) Short Interest Update - MarketBeat

Nov 18, 2024
pulisher
Nov 16, 2024

Editas Medicine stock hits 52-week low at $2.7 amid market challenges - Investing.com India

Nov 16, 2024
pulisher
Nov 12, 2024

Editas Medicine's SWOT analysis: gene editing stock faces pivotal phase - Investing.com

Nov 12, 2024
pulisher
Nov 08, 2024

Cantor Fitzgerald Expects Lower Earnings for Editas Medicine - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

FY2024 EPS Estimate for Editas Medicine Raised by Analyst - MarketBeat

Nov 08, 2024
pulisher
Nov 07, 2024

Vertex Pharmaceutic (VRTX-Q) QuotePress Release - The Globe and Mail

Nov 07, 2024
pulisher
Nov 07, 2024

TSX Real Estate Capped Index (TTRE) QuotePress Release - The Globe and Mail

Nov 07, 2024
pulisher
Nov 07, 2024

TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail

Nov 07, 2024
pulisher
Nov 07, 2024

Dow Jones Industrials Average (DOWI) QuotePress Release - The Globe and Mail

Nov 07, 2024
pulisher
Nov 07, 2024

TSX Global Gold Index (TTGD) QuotePress Release - The Globe and Mail

Nov 07, 2024
pulisher
Nov 07, 2024

TSX Oil and Gas EW Index (TXOE) QuotePress Release - The Globe and Mail

Nov 07, 2024
pulisher
Nov 07, 2024

S&P 500 Index (INX) QuotePress Release - The Globe and Mail

Nov 07, 2024
pulisher
Nov 07, 2024

Bristol-Myers Squibb Company (BMY-N) QuotePress Release - The Globe and Mail

Nov 07, 2024
pulisher
Nov 07, 2024

Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market EvolutionTechnavio - The Malaysian Reserve

Nov 07, 2024
pulisher
Nov 07, 2024

FY2024 EPS Estimate for Editas Medicine Lifted by Analyst - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

Editas Medicine, Inc. (NASDAQ:EDIT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Nov 07, 2024
pulisher
Nov 06, 2024

Editas Medicine upgraded at Evercore on CRISPR platform - Seeking Alpha

Nov 06, 2024
pulisher
Nov 06, 2024

Editas Medicine to Participate in Upcoming Investor Conferences - GlobeNewswire

Nov 06, 2024
pulisher
Nov 06, 2024

Editas Medicine to Present at 3 Major Healthcare Investor Conferences | EDIT Stock | EDIT Stock News - StockTitan

Nov 06, 2024
pulisher
Nov 06, 2024

Analysts Are Betting On Editas Medicine, Inc. (NASDAQ:EDIT) With A Big Upgrade This Week - Simply Wall St

Nov 06, 2024
pulisher
Nov 06, 2024

Growth Investors: Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 19% - Yahoo Finance

Nov 06, 2024
pulisher
Nov 06, 2024

Editas downgraded to market perform by Raymond James - MSN

Nov 06, 2024
pulisher
Nov 05, 2024

Editas Medicine (FRA:8EM) Total Inventories : €0.00 Mil (As of Sep. 2024) - GuruFocus.com

Nov 05, 2024
pulisher
Nov 05, 2024

Chardan Capital Reiterates Buy Rating for Editas Medicine (NASDAQ:EDIT) - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

Editas Medicine Buy rating and $12 target reaffirmed by Chardan - Investing.com UK

Nov 05, 2024
pulisher
Nov 05, 2024

Chardan Capital Markets Reiterates Buy Rating on Editas Medicine (EDIT) - StreetInsider.com

Nov 05, 2024
pulisher
Nov 05, 2024

Editas Medicine Downgraded by Raymond James Amid Strategic Shift and Program Uncertainty - GuruFocus.com

Nov 05, 2024
pulisher
Nov 05, 2024

Editas Medicine maintains Perform rating at Oppenheimer By Investing.com - Investing.com UK

Nov 05, 2024
pulisher
Nov 05, 2024

Royal Bank of Canada Lowers Editas Medicine (NASDAQ:EDIT) Price Target to $5.00 - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

Editas Medicine (NASDAQ:EDIT) Issues Quarterly Earnings Results, Hits Expectations - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

Editas Medicine target cut to $5 by Barclays on strategic outlook - Investing.com Canada

Nov 05, 2024
pulisher
Nov 05, 2024

Editas Medicine Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance

Nov 05, 2024
pulisher
Nov 05, 2024

Editas Medicine (EDIT) PT Lowered to $5 at Barclays - StreetInsider.com

Nov 05, 2024
pulisher
Nov 05, 2024

Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates - MSN

Nov 05, 2024
pulisher
Nov 05, 2024

Truist cuts Editas Medicine target to $8, keeps buy rating By Investing.com - Investing.com Canada

Nov 05, 2024
pulisher
Nov 04, 2024

Editas Medicine Reports Q3 2024 Results and Developments - TipRanks

Nov 04, 2024
pulisher
Nov 04, 2024

Editas: Q3 Earnings Snapshot - The Washington Post

Nov 04, 2024
pulisher
Nov 04, 2024

Editas Medicine (EDIT) PT Lowered to $5 at RBC Capital - StreetInsider.com

Nov 04, 2024
pulisher
Nov 04, 2024

Editas downgraded to market perform by Raymond James (NASDAQ:EDIT) - Seeking Alpha

Nov 04, 2024
pulisher
Nov 04, 2024

Editas Medicine (NASDAQ:EDIT) Downgraded by Raymond James to "Market Perform" - MarketBeat

Nov 04, 2024
pulisher
Nov 04, 2024

Editas Medicine (EDIT) PT Lowered to $8 at Truist Securities - StreetInsider.com

Nov 04, 2024
pulisher
Nov 04, 2024

Editas Medicine earnings matched, revenue fell short of estimates By Investing.com - Investing.com Canada

Nov 04, 2024
pulisher
Nov 04, 2024

Editas Medicine Announces Third Quarter 2024 Results and Business Updates - The Manila Times

Nov 04, 2024
pulisher
Nov 01, 2024

Editas Medicine stock hits 52-week low at $2.9 amid market challenges - Investing.com Australia

Nov 01, 2024
pulisher
Oct 31, 2024

Is Editas Medicine, Inc. (EDIT) a Promising Gene Editing Stock? - Insider Monkey

Oct 31, 2024

Editas Medicine Inc Azioni (EDIT) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Capitalizzazione:     |  Volume (24 ore):